ODAC Finds Study Data Inadequate to Recommend Evacet
November 1st 1999SILVER SPRING, Md-The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has voted 9 to 2 against recommending approval of Evacet (doxorubicin HCl liposome injection, The Liposome Company) for the first-line treatment of metastatic breast cancer in combination with cyclophosphamide. The vote against Evacet came after Liposome presented three controlled, randomized studies.
Enhancing Quality of Life an Important Treatment Endpoint
November 1st 1999VIENNA, Austria-When cure or prolongation of survival is no longer a reasonable possibility, enhancing the cancer patient’s quality of life becomes the preeminent objective of treatment, Ian Tannock, MD, of the Princess Margaret Hospital, Toronto, said at the 10th European Cancer Conference (ECCO 10). “Quality of life is not a soft endpoint and, when measured appropriately, is every bit as reproducible as so-called objective measures such as tumor response,” he said.
NCI Explores Ways to Speed Development of Imaging Methods
November 1st 1999BETHESDA, Md-Representatives from government, industry, and aca-demia met for a day and half to discuss the barriers that limit more rapid development of imaging techniques needed by cancer researchers and physicians-and possible ways to overcome them.
Surgery, Adjuvant Therapy Are Improving Survival in GI Cancers
November 1st 1999BUFFALO, NY-Recent advances in adjuvant therapies have begun to improve survival outcomes and quality of life for patients with gastrointestinal tumors such as pancreatic carcinomas and colorectal cancers metastatic to the liver. But the role of the surgeon remains critical.
Memorial Introduces Integrative Medicine Service to the Public
November 1st 1999NEW YORK-A Memorial Sloan-Kettering Cancer Center public forum held to introduce the public to the hospital’s new complementary medicine service drew repeated bursts of applause and expressions of thanks from the patients, family, and community members who attended. The audience not only heard from practitioners but also saw slides of relaxing visual imagery, meditated to the sound of a crystal bowl rim being rubbed, and listened to the music of a trio of music therapists.
Sustained-Release Cytarabine for Lymphomatous Meningitis
October 1st 1999ATLANTA-Administration of DepoCyt, a novel sustained-release formulation of cytarabine (ara-C), proved favorable with acceptable safety in the first randomized, controlled trial of any drug for lymphomatous meningitis, Stephen B. Howell, MD, said at the 35th annual meeting of the American Society of Clinical Oncology (ASCO).
Scintimammography Detects Tumors in Dense Breast Tissue
October 1st 1999NEW ORLEANS-Scintimam-mography utilizing a radionuclide already approved by the FDA for cardiac imaging has been shown to compare favorably with standard mammography in a new study presented at the 99th annual meeting of the American Roentgen Ray Society.
Risk Factors for Local Recurrence After Breast-Conserving Therapy
October 1st 1999NEW ORLEANS-In women treated with a breast-conserving approach for early-stage invasive breast cancer, “adequate” excision of the primary tumor is necessary to obtain optimal local tumor control. But what constitutes an adequate excision prior to radiation therapy, and what are the risk factors for local recurrence? A Harvard pathologist discussed this issue at the American Society of Breast Disease annual meeting.
New Brain Imaging Technique Cuts MR Scan Time in Half
October 1st 1999NEW ORLEANS-A new technique for magnetic resonance (MR) imaging can reduce brain scan time by half, according to a study from the Department of Radiology, University of Vienna, reported at the 99th annual meeting of the American Roentgen Ray Society. The new technique, T1-3D-echo-planar-imaging (EPI)-sequence, has diagnostic utility comparable to conventional T1-3D-gradient echo-sequence imaging, said lead investigator, Ahmed Ba-ssalamah, MD.
Laparoscopic Surgery Offers Important Benefits for Patients With Colorectal Disease
October 1st 1999Laparoscopic operating techniques are gaining wider acceptance among colorectal surgeons, as their efficacy is proven. These techniques offer patients the advantages of fewer complications, decreased need for postoperative narcotics, faster
Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art
October 1st 1999PHILADELPHIA-“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.
Geffen Cancer Center Uses Western Medicine, Eastern Philosophy
October 1st 1999ARLINGTON, Va-Studies indicate that about half of cancer patients are now using complementary and alternative therapies, a finding that is motivating many medical oncologists to discuss such therapies with their patients and make recommendations about their use.
Tamoxifen Plus Goserelin as Adjuvant Therapy
October 1st 1999VIENNA, Austria-In a group of estrogen- or progesterone-positive breast cancer patients, combination endocrine treatment using goserelin (Zoladex) and tamoxifen (Nolvadex) significantly reduced the number of recurrences and increased disease-free survival, compared with CMF, after a median follow-up of 4 years, said Reimond Jakesz, MD, of the Department of General Surgery, University of Vienna, Austria.
New Developments in PET Aid Diagnosis, Rx of Cancers
October 1st 1999NEW YORK-Nuclear medicine-based imaging techniques are now being used to refine treatment strategies for cancer patients, with positron emission tomography (PET) at the forefront. Patients with complex cancers of the brain, head and neck, thyroid, and lung are now able to receive more refined and accurate diagnoses through new PET techniques, four speakers said at a nuclear medicine conference sponsored by Memorial Sloan-Kettering Cancer Center and Johns Hopkins University School of Medicine.
Participants in Chemotherapy Trials Incur Minimal Excess Cost
October 1st 1999Cancer patients enrolled in chemotherapy clinical trials at the Mayo Clinic in Rochester, Minnesota, incurred a 5-year average cost of $46,424, compared to $44,133 for matched control patients who were not trial participants, suggesting that
Court Says FDA Can’t Restrict Off-Label Drug Use Materials
October 1st 1999WASHINGTON-A federal judge has declared unconstitutional several sections of the Food and Drug Administration Modernization Act (FDAMA) that regulate the ability of pharmaceutical companies to distribute to physicians certain materials regarding off-label uses of drugs.
Be Alert for Other Possible Causes When Assessing CNS Side Effects of Opioids
October 1st 1999VIENNA, Austria-Among the CNS effects of opioids are cognitive failure, organic hallucinations, myoclonus, hyperalgesia, and severe sedation. “Regular, repeated assessments of cognition should be performed in patients taking opioids, and any changes should be evaluated by the physician to exclude other underlying etiologies,” Carla Ripamonti, MD, said at the World Congress on Pain.
Radiofrequency Ablation Shows Promise for Inoperable Liver Tumors
October 1st 1999Kim Jessup, MD, professor of surgery and director of the Gastrointestinal Oncology Program at the University of Pittsburgh Cancer Institute, is using radiofrequency ablation to dissolve tumors that have spread from the colon to the liver. According
Strang Program Integrates Standard and Complementary Therapies
October 1st 1999NEW YORK-A person-centered holistic approach to the practice of oncology involves the integration of current state-of-the-art Western therapies with nutritional supplementation and other less traditional methods, including meditation, music and sound therapy, and guided imagery techniques, said Mitchell L. Gaynor, MD, director of medical oncology and of the Integrative Medicine Program, Strang-Cornell Cancer Prevention Center, New York.
Interferon Significantly Affects Metabolism of Other Drugs Given to Cancer Patients
October 1st 1999Given to Cancer Patients Cancer patients undergoing therapy with interferonalfa-2b (IFN-a-2b [Intron A]) are possibly being overmedicated with the narcotics and antidepressants commonly administered with this agent, according to a University
Rate of Decline in AIDS Deaths Falls by More Than Half
October 1st 1999ATLANTA-AIDS deaths fell by 20% between 1997 and 1998, but this was a significantly smaller decline than the 42% fall in mortality that occurred between 1996 and 1997, according to data released by the Centers for Disease Control and Prevention (CDC).
Study Shows Direct Link Between H Pylori and Gastric Cancer
October 1st 1999ORLANDO-Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.
States Lag in Committing Tobacco Funds to Antismoking Efforts
October 1st 1999WASHINGTON-Only six of the states that settled their lawsuit with the tobacco industry last year have so far “provided enough new funding for truly comprehensive tobacco prevention and cessation programs,” according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association. The six states are Hawaii, Maryland, Minnesota, Vermont, New Jersey, and Washington.
NIH to Launch New On-Line Repository for Life Sciences Research
October 1st 1999BETHESDA, Md-The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/PubMed/.
Smoking Rates Fell Significantly in 1998, But Continued to Rise Among Young Adults
October 1st 1999ROCKVILLE, Md-Although cigarette smoking has remained relatively stable among youths age 12 to 17 since 1988, the percentage of young adults who smoke rose sharply between 1994 and 1998. According to a new government survey, 41.6% of Americans age 18 to 25 were cigarette smokers last year, up from 34.6% in 1994 and 40.6% in 1997.
Radiofrequency Ablation Used to Treat Liver Metastases
October 1st 1999BETHESDA, Md-Radiofrequency ablation (RFA) is being used to “cook” tumors where they lie and may be particularly useful for destroying liver metastases. This quick, nontoxic, relatively noninvasive approach will soon be tested in clinical trials, Bradford Wood, MD, of Georgetown University Medical Center and the National Institutes of Health, said in an interview.
PET, Lymphoscintigraphy Expanding Into the Clinic
October 1st 1999LOS ANGELES-“PET has arrived!” Edward Coleman, MD, said at a press conference held during the 46th annual meeting of the Society of Nuclear Medicine. Dr. Coleman, professor of radiology and director of the Nuclear Medicine Division, Duke University Medical Center, noted that “PET has expanded tremendously into the clinical environment.” He attributes this to the development of fluorodeoxyglucose (FDG) PET imaging and PET’s growing applications in oncology.